chadox1.hivconsv62
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 2, 2024 (NCT06071767)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07054931 | Phase 2 | Sep 5, 2025 | University of Oxford |
| NCT06484335 | Phase 1 | Feb 1, 2025 | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Army |
| NCT06071767 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2024 | Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, University of Pittsburgh |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 2 | 1 | 1 | 2024 |
| Gilead Sciences | For profit | 1 | 0 | 1 | 2024 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2024 |
| United States Army | Government | 1 | 0 | 1 | 2025 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2024 |
6 organizations
Page 1 / 1